Jamie Heywood, Co-Founder of PatientsLikeMe
This week on Conversations on Health Care, Mark and Margaret speak with Jamie Heywood, Co-Founder of PatientsLikeMe, an online medical data-sharing portal for patients experiencing a variety of diseases. He is also founder of the ALS Therapy Development Institute, a nonprofit biotech research organization seeking a cure for Lou Gherig’s Disease. He talks about his goal of transforming medical care through patients sharing in-depth data with the public and the medical community to facilitate better treatments and disease outcomes.
(Music)
Mark Masselli: Welcome to Conversations on Health Care. I am Mark Masselli.
Margaret Flinter: And I am Margaret Flinter.
th,
Mark Masselli: Well Margaret, today is leap day, February 29 and it's a rare
day, only comes around once every four years.
Margaret Flinter: Well, that makes it special but it's also another designated day
and a really pretty serious one and that is Rare Disease Day today, February
th
29 .
Mark Masselli: I did know that and there are surprisingly some 7000 identified
rare diseases which pose a problem. Often they don’t get the funding more
prevalent diseases get for research so those communities often suffer without
treatment breakthroughs.
Margaret Flinter: That’s right Mark, and they suffer in part because they are also
referred to as orphan diseases meaning that there just isn’t that large organized
constituency out there advocating for more research or more investment. So the
motivation behind this day, as I understand it, is to get the patient communities
that suffer from these rare diseases more connected to researchers and to each
other in the hope of finding faster routes to cures for the disease. And that is
something that today’s guest, PatientsLikeMe Founder, Jamie Heywood knows a
lot about and we will be talking to him a little bit later.
Mark Masselli: But Margaret, just before we get to Jamie, I wanted to mention
that we are at another turning point in the country’s move to switching over to the
adoption of electronic health records.
Margaret Flinter: And yeah, we are at that next step. The CDC released its next
wave of guidelines for a meaningful use of electronic health records. This is
Phase II I believe. And adopting these electronic health records we know will
reduce medical mistakes, streamline efficiencies and cost but still, we have got
that big lag in switching over throughout the country with not yet having hit the
tipping point of more than half the practices in the country being on electronic
health records.
Mark Masselli: Well they are working on it very hard and the National Health
Information Coordinator, Farzad Mostashari who has been on this show last
week announced the second phase of meaningful use of the electronic health
record and it poses perhaps the biggest challenge. Stage II calls for electronic
health record systems to be interoperable, or more simply put, be able to talk to
each other, something that just isn’t happening enough of.
Margaret Flinter: And Mostashari said that perhaps because of that they are
extending the deadline for complying with Stage I. The deadline for switching to
electronic health records has been moved from 2011 to 2014. Dr. Mostashari
released the proposed rules. Of course they are open for comment for a period
of time and for those of you who are interested in details, they are all up on the
web and take a look.
Mark Masselli: Meanwhile, Jamie Heywood has been in the frontlines of battling
one rare disease ALS, better known as Lou Gehrig's disease, a rare fatal
condition that afflicted his brother in 1999. He founded the ALS Therapy
Development Institute and has raised the bar on ALS research.
Margaret Flinter: And from that effort, he created PatientsLikeMe, an online
personal medical data sharing portal that strives to make as much meaningful
information openly available to researchers seeking better cures and better
treatments. He thinks it’s going to revolutionize how health care is delivered and
engaged in by patients of all kinds.
Mark Masselli: But no matter what the story, you can find all of our shows and
hear more of us by Googling CHC Radio, and as always, if you have feedback,
email us at www.chcradio.com , we would love to hear from you. Coming up our
conversations with PatientsLikeMe Cofounder, Jamie Heywood but first, here’s
our producer Marianne O'Hare with this week’s Headline News.
(Music)
Marianne O'Hare: I am Marianne O'Hare with this Headline News. Health care
reform was a big and sometimes contentious topic this past weekend as
governors from around the nation met in Washington. At issue, the Obama
Administration’s order that states set up state-based insurance exchanges for
uninsured residents to purchase health insurance at a reasonable rate. While
states like Connecticut, California and Maryland are already up-to-speed on that
order, many states, most of them GOP-led, are opting to wait until after the
Supreme Court rules on the Affordable Care Act, which will come before the High
Court at the end of March with the decision expected in June. Some GOP
governors like Dave Heineman of Nebraska is saying they are just going to adopt
a wait and see attitude before complying. Meanwhile, all of the controversies
springing from conservative measures on things like birth control funding and the
Affordable Care Act are creating an uptake in support for President Obama in
one formidable sector, women voters. Obama’s approval rating on matters like
employment and the economy have jumped 10% for him since December among
women. Analysts believe issues such as his stance on support for birth control
are the underlying factors in the increased approval.
From the medical grounds, it appears that flu has been slow to take hold
because of all this mild weather. Folks are spending less time cooped up inside
spreading that flu bug around. There is another theory for the late start though.
This year’s flu is genetically similar to last year’s showing last year’s flu shot may
still have a prophylactic effect.
And we know it makes dishes taste tastier but Rosemary may have a positive
mental effect as well. A recent study showed those exposed to Rosemary oils in
a control group had higher functioning cognition and a slightly elevated mood.
How is that for a savory bit of information? I am Marianne O'Hare with this
Headline News.
(Music)
Margaret Flinter: Today, Margaret and I are speaking with Jamie Heywood,
Industrial Engineer, Founder and CEO of PatientsLikeMe, the preeminent online
data sharing platform for patients with a variety of diseases. He is also a
Cofounder of ALS Therapy Development Institute. Jamie, welcome to
Conversations on Health Care.
Jamie Heywood: It's great to be here.
Mark Masselli: Jamie, you launched ALS TDI, the first non-profit biotech
company in the world after your brother was diagnosed with ALS better known as
Lou Gehrig's disease back in 1998. That quest led ultimately to the founding of
PatientsLikeMe which allows patients to openly share their medical data for
research. You were not a health care insider but you saw the need for an open
research model for accelerating therapeutic research. So what is so different
about the model you created?
Jamie Heywood: Well I think in the beginning I came at this from the perspective
of Stephen, which is how do I find answers for Stephen. And with the disease
like ALS where you are sort of given a death sentence of three years or so, your
primary objective is initially to discover a new treatment, something that delays
the disease. And I had disadvantage of having an academic father and then
working at an institution that was doing basic neuroscience and sort of knowing
some of the strengths and weaknesses of the current system. So I kind of did
what an engineer does which is to look at the problem and sort of industrialize it
and say what are the ways we need to move forward to find a treatment for
Stephen, and that’s what led to the Institute. And then once Stephen was fairly
sick with the disease, we had to manage this very complex disorder at home and
I was realizing that most of what I was learning was from other patients and it
wasn’t necessarily just what to do to treat the disease or manage symptoms but
more about how do you live your life with disease well, which is I think where the
medical system really falls down, doesn’t give that answer. So, PatientsLikeMe
sort of came out of an intersection of that quantitative assessment of disease that
relates to discovery and then this need to understand how to live your life as a
patient and how that be quantified and exchangeable and understandable.
Margaret Flinter: So Jamie, I think that it really was an incredible innovation that
you created because when you started PatientsLikeMe there was nothing like it,
there was no portal for patients where they could safely and publicly share their
medical data and share with each other, with other people suffering from the
same illnesses. And I wonder for our listeners, how do they find their way to
PatientsLikeMe, what do they do when they get there, and what are these two
pathways of both sharing support with other people and experience with other
people that helps them live with it but also sharing their data? What is this data
that they share? Maybe you could sort of walk that walk as a patient would
today.
Jamie Heywood: Let's say that you are mid 30s and you just got diagnosed with
Multiple Sclerosis and you have these weird symptoms of pain and maybe some
interference in your ability to see and walk, and you have no idea what's going to
happen. And you go and you find a great doctor, and you get a second opinion
and you really confirm that you have this process and maybe they put you on the
first line treatment and you go home. And the question you ask is, how does this
affect my relationship, how does this affect my ability to work, is it going to get
worse, is it going to get better, will these problems that I have from taking the
drug, these side effects, go away or will they get worse overtime. And you
probably asked all of those questions of your doctor and they might have given
you pretty good answers from their perspective. But you are home, and you just
had a fight with your husband because your sex drive is down and you can't
figure out how to connect and relate, and you got to go talk to someone else like
you to figure out what's the path, how can you live a great life even with this
problem. And you start searching and you find our site. It’s not like patients
haven’t networked and helped each other connect and live, we have always done
that through churches and through all kinds of social media. But today, you can
find someone just like you, you can find that 36 years old woman who was
diagnosed two years ago, had the same symptoms as you. You go through the
issues, the dialogue, talk about the consequence of your treatment decisions in
that context and because you are sharing everything, you can find and identify
that person, and that’s where it really comes out. And it’s not like there is one
simple value, it’s that you are in this deep dialogue with the community and you
don’t know what you need to know and you learn.
Mark Masselli: So it’s not anonymous information, it’s you really identify who you
are and all sort of aspects of your condition. How is that translated and how is
that helping out improve outcomes for pharmaceutical companies or other
researchers who are engaged in clinical research?
Jamie Heywood: There are two parts to that. First off, you don’t have to use
your name, in fact most patients don’t give their name, but because you are
sharing so much information, ultimately your condition, sometimes where you
live, the treatments, we don’t want to claim that it’s fully anonymous. People
don’t know who the people are, and if you stay inside the site you are not
indexed by the search engines. And you can learn a lot without even sharing
anything so you can just come and read other people’s information.
The second part, let's just talk about what the sharing experience is like. You
mentioned earlier that it was sort of the ability to share your health records. We
actually do more than health records. And I think this is one of the
misunderstandings about the health system. When I run a clinical trial and I
study a disease or a condition, we measure some really quantitative important
things that help us understand what your status is. When you do medicine, you
don’t actually quantify those things. You take notes, you discuss issues but the
quantification of the health of the patient is only generally done in clinical trials.
And so what we do is we do that quantification. So it’s actually an outcome
management platform not just a health record.
So you really can, just like a trial, know how someone is. And that’s what makes
health care become a discovery tool because right now when a pharmaceutical
company wants to know if a drug actually helps anyone in the real world, they
have to ask a system that does clinical outcomes research and that’s what we
bring, the clinical outcomes research to the practice of medicine through the
patient in a collaboration. We find the real value of the patients is through that
triangle of formalizing their understanding of their disease, sharing that and
collaborating with their physician to achieve the best outcome, always in a
framework that a research enterprise or a researcher, an academic, could learn
something from that process of what's your status, what do you do to change it,
what was the result of that.
Margaret Flinter: What's your response when people raise questions of privacy
and protecting people from what some have called exploitation of using the
patients’ data?
Jamie Heywood: It’s hard to imagine the difference between our society seven
years ago, before Facebook, and our society today. We were on the bleeding
edge of sort of a new movement which I would sort of call the Community
Movement which is to say that we are not all islands, we want to collaborate in
ways to create greater shared value. And I think that this shift from seven years
ago when doctors were asking us whether it was legal for a patient to share their
health information, or the patient literally asking the question was it illegal, to
today, where doctors are actively encouraging people to look on the site, is just a
change in our culture. You have a right to privacy. But seeking privacy as a goal
is really built on healthy societies. And if we limit the circle of the people we care
about only to those that live in our neighborhood or in our house or in our family,
we are going to have a very unhealthy society.
When my brother was dealing with ALS, he cared about lots of other people with
the disease. He had things that could help them. And the idea that the privacy
movement would suggest it was a bad idea for him to do so really I think is just
an old concept that’s gone. I think that today these digital tools are allowing
people to sort of follow their human instinct to be parts of the community and
make a difference. And we have used privacy or sometimes I would say secrecy
as a way of preventing discrimination rather than really fundamentally addressing
the question of how do we build a just society that’s not based on secrecy but is
based on justice. And that’s I think the journey we have go through now because
technology is going to make it so that we can know so much about everyone, that
if we don’t figure out how to live together collaboratively with inequality of
conditions and other things then we are not going to be able to build a just culture
we want to live in.
Mark Masselli: We are speaking today with Jamie Heywood, the driving force
behind PatientsLikeMe named one of the 15 companies that will change the
world by CNNMoney. You also co-founded HealthDataRights.org. Really you
started out with a bold declaration of individual rights in today’s social media
climate. Talk to us a little bit about that organization and the issues associated
with the fundamental right to your health information through all means.
Jamie Heywood: Two of us were sitting and talking about how as we were trying
to help patients was not allowed. Like there are actually 27 states where as a
patient you are not allowed to get access to your labs unless your doctor gives
them to you. The idea that someone have information about you that you weren’t
allowed to have access to just sort of felt wrong to us in this modern world. And
we started talking with more people and people really said hey, we really have to
write this down. And over about two weeks, literally 100 really amazing
individuals wordsmithed these very tight concepts that an individual has a right to
a copy of every element of data about their health and if that data exists in a
digital form, in the raw form like the MRI file or whatever, they must be made
available in that form. And it's so simple but it's not the way the system works.
And I think that we need this to enable patients to be the corrective force in
health care, the part that makes the health care be honest and transparent.
Margaret Flinter: But Jamie, if I could maybe take you in just a little bit of a
different direction for a moment, the whole issue of the off-label use of
medication, there are times when pharmaceuticals or treatments have been
developed for one condition, tried in something else not yet been through all the
rigors of all the research to formally give them approval for use in that case and
we call it off-label use. What’s the role that your company has played in bringing
forward some treatments that may be of benefit to a subset of people?
Jamie Heywood: A lot of medicine is not actually evidence-based. And you
could sort of profile the sort of evidence into sort of two categories with a big gray
in-between area. So one is you have these large scale formal clinical trials
where you establish beyond any doubt that a treatment is effective for some
population of patients. And medicine operates at that whole gradient.
Obviously, the right thing to do where if you have the good knowledge you should
do it, and then strong evidence based. But there is also a great deal in the
middle, which is in ALS, in one of treatments is a drug called Elavil that’s used to
manage excess saliva. And these sort of secondary treatments which do not
have formal indications, I mean that’s a side effect of Elavil is dry mouth, don’t
have any evidence for them. And so we have done some work in publishing and
demonstrating that and if you go on our website, you can type in a symptom
name with your condition and you can learn all the treatments that patients
believe helped them with that. And it's belief-based evidence; it’s not the formal
actual measure change evidence that we are developing that.
The other thing we have done is look at side effects of medicine. So if you look
at two drugs for the treatment of fibromyalgia, one is Lyrica and the other is
Cymbalta. They have very different mechanisms. But one of the drugs causes
significant weight gain. If you are a woman and trying to figure out what drug to
take for fibromyalgia and your choices are Lyrica and Cymbalta and you find out
that Lyrica will cause you to gain weight every year, you might change your
choice or the first choice you make with your doctor. And that information is not
obvious, not available so we have done that as well. What I am hoping we can
move to is a learning health system where we really do understand that we allow
for the development of the treatment collaboratively with the population. We
observe and learn what happens in the real world and then the system feeds that
back. It's not moral to provide medical care to someone in any real risk situation
or any place of ambiguity unless you are collecting sufficient information to guide
the next person that goes down that journey. And that’s a pretty radical shift to
thinking about how we do health care which is it’s only about the person in front
of you and you protect their privacy as paramount. But to my mind, if my mom
has breast cancer and she does an experimental treatment against her mutation
that no one else has done, and that information isn’t shared, that’s as big a crime
as not reporting a crime because someone is going to do that and risk their life in
the future and you didn’t give them a chance to do that on the best information,
and we need to really shift our culture to that new model.
Margaret Flinter: It leads me to wonder have you observed, whether it was your
intention or not, have you observed advocacy groups or action coming out of the
community of individuals on PatientsLikeMe. Has that translated into testifying in
Congress or lobbying on behalf of funding for certain diseases, anything that sort
of transcends what happened within PatientsLikeMe into a larger context?
Jamie Heywood: The patients are organizing to evaluate whether treatments
work. So, in MS they are looking at CCSVI which is this sort of surgery that
increases blood flow. People look at diets in fibromyalgia and chronic fatigue.
And then they are also looking at treatments in ALS across the board. There is a
group that are organizing a petition to force the FDA to sort of be more formal
about its Compassionate Access Policies, and I think we are a platform to that.
And then patients just organize together to do specific subtle advocacy issues.
They got involved in the stem cell debate, things that really matter to them.
Mark Masselli: Jamie, one of the initiatives to make patient data more accessible
is the Blue Button Initiative. Talk to us a little bit about that initiative and why are
other data sharing systems not working as effectively.
Jamie Heywood: I mean I think the Federal Government has really done a great
job of leading here. The VA Blue Button with Peter Levin, Todd Park, Farzad
Mostashari, Aneesh Chopra have really pushed for and defined this data liquidity
in health care in a really important way and it's very exciting. Registries really
matter and we are building a lot more and the NIH is investing a ton in that. But
they are still building them in such a way that they can only allow 20 or 100
researchers to access the database because they contain genetic data which is
mostly fingerprints and identifiers, right. It's a little bit like it's the beginning of the
personal computer age. I don’t think anyone can really imagine that normal
human beings that are not epidemiologists or clinical researchers want access to
data and when high school students can do genetic studies on disease, we will
live in this different world and I think the promise is just really complicated leap
across that gap and no one has done it. It’s that’s why those organizations
(20:28 inaudible) matter to me because they are starting that leap. Oh and the
Creative Commons, which has got an organization called Science Commons that
has developed a thing called Open Consent where if a patient consents then
their data can be used by anyone. Think of the irony of that. Until 2011 there
was no document that a human being could sign that would allow anyone in the
world to do research on their information. I mean that’s just so insane.
Mark Masselli: Jamie, we like to ask all of our guests this final question. With all
of your hopes and connections, when you look around the country and the world,
what do you see in terms of innovations and who should our listeners at
Conversations be keeping an eye on?
Jamie Heywood: Sweden has been doing some really amazing work with
registries over the last decade. And medicine in Sweden has moved from being
sort of this formal research process model to this specialists really operating
these registries and collaborating to make the country’s health better and every
individual with that condition. They are lowering costs, but they are not even
trying to do that. What they are really doing is they are just taking better care of
people and that’s a model to my mind I think that we help make possible more
broadly. A country’s wealth is not so much how much money it has but its how
much health it has because health drives everything. It drives how successful
your children will be in the world economy. We have to start viewing health as a
strategic asset and building an economy around health care that maximizes that.
My parents are in their 70s. I want them to be here for my kids for a long time
and I want a model that allows me to invest with them in that making a healthy
fulfilled long health span. And that’s what I think things like Sweden and
registries and platforms like ours make possible.
Margaret Flinter: Today, we have been speaking with Jamie Heywood, Founder
and CEO of PatientsLikeMe, the preeminent online data-sharing platform for
patients with a variety of diseases. Jamie is also the co-founder of the ALS
Therapy Development Institute. Jamie, thank you so much for being with us on
Conversations today.
Jamie Heywood: It's been a pleasure.
(Music)
Margaret Flinter: Each week, Conversations highlights a bright idea about how
to make wellness a part of our communities and everyday lives.
Mark Masselli: One of the directives of the Obama Administration’s Health Care
Reform Act requires pediatricians and health insurers to begin screening kids for
obesity, a condition afflicting one in three American children. The problem, what
to do with those children who are identified as being overweight or obese? It's
tough enough for adults to lose weight even with multiple programs at their
disposal. There are relatively few programs available to overweight children and
their families that aren’t expensive or hospital-based. UnitedHealthcare has
teamed up with the YMCA to create a program for community based weight loss
sessions for kids and teams, launching the pilot program in Providence, Rhode
Island. The kids, accompanied by a parent, joined in a group session that are
fun but also informative. Kids are educated about the calorie counts of food,
learn about Body Mass Index and the importance of exercise on a daily basis. At
the end of the 16 week program, the overweight kids lost an average of 3.5% of
their body fat, and the bonus, the parents and the rest of the family often lost
weight too. The pilot program is inexpensive, kid-directed and life changing. And
with follow up as part of the program, these kids know they will still be challenged
to keep up with healthy lifestyle changes. Helping kids tackle obesity cheaply,
and in a community setting that works for kids and their families, now that’s a
bright idea.
(Music)
Margaret Flinter: This is Conversations on Health Care. I am Margaret Flinter.
Mark Masselli: And I am Mark Masselli, peace and health.
Conversations on Health Care, broadcast from the campus of Wesleyan
University at WESU, streaming live at www.wesufm.org and brought to you by
the Community Health Center.